Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 28, 2026, 7:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126
View directory record Official record
Conditions
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Interventions
EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Active, not recruiting No phase listed Observational

CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer

NCT04495985
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Active, not recruiting Not applicable Interventional

Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery

NCT03012399
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8
Interventions
Hypnosedation, Questionnaire Administration, Verbal Support
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

NCT04439110
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trastuzumab Emtansine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 28, 2026, 7:51 PM EDT
Terminated Not applicable Interventional

Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy

NCT03723863
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage III, Breast Cancer Stage II, Breast Cancer Stage IIA, Breast Cancer Stage IIB, Breast Cancer Stage IIIA, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Breast Cancer
Interventions
Occupational Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

NCT01038804
View directory record Official record
Conditions
Breast Cancer
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 28, 2026, 7:51 PM EDT
Terminated Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

NCT01238133
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 28, 2026, 7:51 PM EDT
Not yet recruiting Phase 2 Interventional

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

NCT07285993
View directory record Official record
Conditions
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions
18F-FAPI-74, 18F-FDG, PET/CT
Drug · Procedure
Lead sponsor
Randy Yeh
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Terminated Phase 2 Interventional Results available

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

NCT00832338
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions
Docetaxel with Cytoxan, Dexamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Not applicable Interventional

Enhancing Exercise in Breast Cancer Survivors

NCT01849978
View directory record Official record
Conditions
Breast Cancer
Interventions
Newsletter about physical activity and breast cancer survivors, Changing your habits brochure, Tips for making exercise enjoyable and personally-valued, Testimonials from breast cancer survivors
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 28, 2026, 7:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

NCT03729115
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
25 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
3
States / cities
La Jolla, California • Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation

NCT02783690
View directory record Official record
Conditions
Breast Cancer
Interventions
Hypofractionation
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 28, 2026, 7:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

NCT03789110
View directory record Official record
Conditions
Breast Cancer
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics

NCT04683120
View directory record Official record
Conditions
Oncology, Breast Cancer, Cancer Diagnosis, Margins of Excision, Margins, Tumor-Free
Interventions
Zenith FLIM Diagnostics
Diagnostic Test
Lead sponsor
Laser LabCorp
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 28, 2026, 7:51 PM EDT
Completed No phase listed Observational

Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer

NCT02830282
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood Collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 28, 2026, 7:51 PM EDT
Recruiting Phase 2 Interventional

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer

NCT06855524
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Breast Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Oligo-fucoidan, Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

NCT00754325
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dasatinib, Fulvestrant
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
28
States / cities
Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer

NCT00107276
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine, cyclophosphamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
145
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Castro Valley, California + 97 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Early Phase 1 Interventional

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

NCT01467310
View directory record Official record
Conditions
Breast Cancer
Interventions
GSK1120212
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Not applicable Interventional

Reducing Distress and Depressive-symptoms in Rural Women

NCT03465813
View directory record Official record
Conditions
Breast Cancer, Psychological Adjustment
Interventions
CaringGuidance After Breast Cancer Diagnosis
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 28, 2026, 7:51 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors

NCT01177124
View directory record Official record
Conditions
Breast Cancer
Interventions
MBSR 6 Weeks Program
Behavioral
Lead sponsor
Cecile Lengacher
Other
Eligibility
21 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 28, 2026, 7:51 PM EDT